Cosmetic cross-reference

Octopamine

CAS 104-14-3

Octopamine (CAS 104-14-3) is a Phase 2 pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Octopamine

CAS Number

104-14-3

UNII

14O50WS8JD

InChIKey

QHGUCRYDKWKLMG-UHFFFAOYSA-N

ChEMBL ID

CHEMBL53929

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2

Mid-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL53929 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 9 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	Potency	14618.984615384614 nM	13	-
-	AC50	2394 nM	3	-
-	EC50	662 nM	2	-
-	IC50	19976.309999999998 nM	1	-
5-hydroxytryptamine receptor 3A Ion channel	EC50	7.62	-	Homo sapiens
Trace amine-associated receptor 1 GPCR	EC50	5.8	-	Homo sapiens
Trace amine-associated receptor 1 GPCR	EC50	5.9	-	Rattus norvegicus
Trace amine-associated receptor 1 GPCR	EC50	5.8	-	Mus musculus
TyR1 GPCR	EC50	6.01	-	Chilo suppressalis

SOURCE IUPHAR/BPS 3 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
TA 1 receptor TAAR1	Full agonist	4.8 pEC50	11459929\|18524885\|17038507\|19725810\|22073124
TA 1 receptor Taar1	Full agonist	5.4 pEC50	17212650\|19725810
TA 1 receptor Taar1	Full agonist	5.9 pEC50	11723224

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Octopamine used for in pharmaceutical contexts?

Octopamine (CAS 104-14-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Octopamine?

No adverse-event association or SIDER side-effect rows are rendered for Octopamine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Octopamine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for OCTOPAMINE with EU status "restricted".

What clinical phase is Octopamine in?

Octopamine is rendered with ChEMBL max phase 2.

What bioactivity targets are documented for Octopamine?

Octopamine has 9 bioactivity rows in this page query. Rendered target entries include 5-hydroxytryptamine receptor 3A, Trace amine-associated receptor 1, TyR1.